Blueprint
 
FORM 6-K
 
 
 
SECURITIES AND EXCHANGE COMMISSION

 
Washington D.C. 20549
 
 
 
Report of Foreign Issuer
 
 
 
Pursuant to Rule 13a-16 or 15d-16 of

 
the Securities Exchange Act of 1934 
 
 
 
For period ending 21 April 2017 
 
GlaxoSmithKline plc
 
(Name of registrant)

 
980 Great West Road, Brentford, Middlesex, TW8 9GS
 
(Address of principal executive offices)
 
 
 
Indicate by check mark whether the registrant files or
 
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
 
 
Form 20-F x     Form 40-F

 
 
 
--

 
 
 
Indicate by check mark whether the registrant by furnishing the
 
information contained in this Form is also thereby furnishing the
 
information to the Commission pursuant to Rule 12g3-2(b) under the
 
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
   
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
 
Volume(s)
 
£16.47
 
910.450
 
£16.47
 
1,756.522
 
£16.47
 
2,998.638
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
5,665.610
£16.47 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
1,367.102
 
£16.47
 
1,752.027
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
3,119.129
£16.47 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
   
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
349.698
 
£16.47
 
440.757
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
790.455
£16.47
 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
2,973.255
 
£16.47
 
3,220.155
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
6,193.410
£16.47
 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
662.840
£16.47
 
722.300
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
1,385.140
£16.47 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
  
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
   
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
3,107.069
 
£16.47
 
3,502.071
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
6,609.140
£16.47
 
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
   
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
1,087.465
 
£16.47
 
1,269.488
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
2,356.953
£16.47
  
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
1,449.959
 
£16.47
 
1,597.807
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
3,047.766
£16.47
  
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
838.910
 
£16.47
 
919.292
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
1,758.202
£16.47
  
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
  
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
 
3,015.919
 
£16.47
 
3,720.939
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
6,736.858
£16.47
  
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
  
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.47
175.499
£16.47
185.700
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
361.199
£16.47
 
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
 
n/a
 
 
 
 
 
SIGNATURES
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: April 21, 2017 
 
 
 
 
By: VICTORIA WHYTE
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc